Leonard F Liebes
Affiliation: New York University
- The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivoMichael T Buckley
Urology, New York University School of Medicine, New York, USA
J Transl Med 5:49. 2007....
- High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanateL Liebes
Division of Oncology, Department of Medicine, New York University Medical Center, New York, New York 10016, USA
Anal Biochem 291:279-89. 2001..The applicability of the methodology to pharmacokinetic studies of PEITC in humans is demonstrated...
- Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology GroupH Hochster
Kaplan Cancer Center and New York University Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY, USA
J Clin Oncol 17:2553-61. 1999....
- Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton
New York University School of Medicine, New York, NY, USA
J Clin Oncol 23:6107-16. 2005..We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to determine the recommended phase II dose and toxicity profile, and the extent of 20S proteasome inhibition obtained...